Please ensure Javascript is enabled for purposes of website accessibility

Shares of Amarin Down 68% After Losing a Patent Lawsuit for Vascepa

By Brian Orelli, PhD - Mar 30, 2020 at 8:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Judge rules that the patents were obvious.

Shares of Amarin (AMRN 8.51%) were down 68% at 7:27 p.m. EDT in after hours trading, after a judge in the U.S. District Court of Nevada ruled for generic-drug makers Hikma Pharmaceuticals (HKMP.Y 3.29%) and Dr. Reddy's Laboratories (RDY 1.04%) in a lawsuit with Amarin over patents on Amarin's fish oil drug, Vascepa, which is approved to treat patients with inflated triglyercide levels.

Hikma and Dr. Reddy's filed abbreviated new drug applications (ANDAs) with the Food and Drug Administration to sell generic versions of Amarin's Vascepa, which prompted a lawsuit from Amarin claiming that the generics infringed on the company's patents.

Following a trial in January, the judge ruled today that the "defendants' proposed ANDA products will induce infringement of the asserted claims, but all the asserted claims are invalid as obvious."

One of the requirements for a patent claim is that the use isn't so obvious that it would be easy to realize that the invention could be used for the proposed use. Hikma and Dr. Reddy's obvious argument was based on the fact that GlaxoSmithKline's (GSK -4.32%) Lovaza, another fish oil product, was already approved as a treatment for high triglyceride levels.

Courthouse building

Image source: Getty Images.

Amarin's Vascepa sales increased 87% to $430 million in 2019 after Amarin showed that the drug improved cardiovascular outcomes in patients with moderately high triglyceride levels. The drug has been on the market since 2012 for patients with extremely high triglyceride levels, but the new data increased the potential market substantially.

Neither Hikma nor Dr. Reddy's has gained FDA approval for their generic drugs, and Amarin said it plans to seek a preliminary injunction to block the launch of a generic while the biotech files an appeal to the judges' decision.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.53 (8.51%) $0.12
GSK Stock Quote
GSK
GSK
$38.30 (-4.32%) $-1.73
Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
RDY
$53.46 (1.04%) $0.55
Hikma Pharmaceuticals PLC Stock Quote
Hikma Pharmaceuticals PLC
HKMP.Y
$39.18 (3.29%) $1.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.